Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kirsten Smith

Surgery San Antonio, TX Medical Doctor

NPI 1700095155 CMS profile 349976

7700 Floyd Curl Dr, San Antonio, TX 78229

Open in the dashboard

General payments

$84,146

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kirsten Smith of San Antonio, TX is reported in the CMS Open Payments database as having received $84,146 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,016 11
2024 General $43,489 21
2023 General $28,859 23
2022 General $2,368 20
2021 General $47 3
2019 General $368 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirsten Smith
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Kirsten Smith were reported at $9,016. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Kirsten Smith Surgery median Middle half National median
2019 $368 $253 $82–$1,521 $163
2020 $0 $131 $40–$706 $114
2021 $47 $168 $50–$904 $132
2022 $2,368 $224 $76–$1,218 $149
2023 $28,859 $253 $82–$1,255 $160
2024 $43,489 $279 $90–$1,381 $164
2025 $9,016 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $82,874 43 payments
  2. KCI USA, Inc $325 1 payment
  3. Smith+Nephew, Inc. $187 9 payments
  4. Integra LifeSciences Corporation $150 2 payments
  5. AbbVie, Inc. $132 7 payments
  6. Organogenesis Inc. $132 6 payments
  7. Paratek Pharmaceuticals, Inc. $124 1 payment
  8. Melinta Therapeutics, Inc. $55 3 payments
  9. Tactile Systems Technology Inc $52 3 payments
  10. Medline Industries, Inc. $32 2 payments
  11. Other $84 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $45,500 4 payments
  2. Travel and Lodging $15,179 19 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,854 2 payments
  4. Education $5,900 3 payments
  5. Honoraria $4,400 1 payment
  6. Food and Beverage $3,739 49 payments
  7. Consulting Fee $1,575 3 payments
Products named General payments · program years 2019–2025
  1. Kerecis Omega3 SurgiClose Wound Care $73,839 31 payments
  2. Kerecis Omega3 Marigen Wound Care $45,367 21 payments
  3. Kerecis Omega3 Marigen Wound Care $43,124 18 payments
  4. Kerecis Omega3 Marigen Wound Care $43,124 18 payments
  5. Kerecis Omega3 Marigen Wound Care $43,124 18 payments
  6. Kerecis Omega3 GraftGuide $30,715 13 payments
  7. Kerecis Omega3 SurgiClose Wound Care $28,472 10 payments
  8. Kerecis Omega3 Marigen Wound Care $28,472 10 payments
  9. Kerecis Omega3 SurgiClose Wound Care $28,472 10 payments
  10. Kerecis SurgiClose $9,016 11 payments
  11. Other $42,543 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

201

Median for General Surgery: 59

Drug cost

$12,332

Median for General Surgery: $393

Branded share of claims

24.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 14 $10,147
Mupirocin Generic 112 $904
Ssd Silver Sulfadiazine Brand 36 $698
Silver Sulfadiazine Generic 18 $317
Triamcinolone Acetonide Generic 21 $266

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$240,052

Medicare's payments for the services billed

Medicare patients

188

Average age 79

Services billed

2,120

93 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 51%
Diabetes 49%
Chronic kidney disease 48%
Atrial fibrillation 38%
Heart failure 32%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record